Recent Updates
Recently added Catalysts
Drug Modality Leaderboard
Top biotechs by clinical-trial depth in each drug modality. Counts include all upcoming trials (completion date ≥ 2026-02) from ClinicalTrials.gov.
Monoclonal antibody
2,203 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  AZNAstraZeneca PLC | 250 | 114 | $275.2B |
| 2 |  MRKMerck & Company, Inc. | 169 | 71 | $302.3B |
| 3 |  JNJJohnson & Johnson | 128 | 50 | $564.1B |
| 4 |  REGNRegeneron Pharmaceuticals, Inc. | 120 | 28 | $67.0B |
| 5 |  BMYBristol-Myers Squibb Company | 117 | 30 | $121.4B |
| 6 |  ABBVAbbVie Inc. | 104 | 27 | $380.6B |
| 7 |  NVSNovartis AG | 99 | 32 | $277.7B |
| 8 |  SNYSanofi | 96 | 22 | $107.4B |
| 9 |  LLYEli Lilly and Company | 78 | 35 | $1.0T |
| 10 |  AMGNAmgen Inc. | 78 | 28 | $177.2B |
Small molecule
1,496 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | AZNAstraZeneca PLC | 129 | 41 | $275.2B |
| 2 | NVSNovartis AG | 108 | 31 | $277.7B |
| 3 | ABBVAbbVie Inc. | 97 | 36 | $380.6B |
| 4 | MRKMerck & Company, Inc. | 91 | 34 | $302.3B |
| 5 | BMYBristol-Myers Squibb Company | 77 | 26 | $121.4B |
| 6 |  PFEPfizer, Inc. | 69 | 21 | $147.6B |
| 7 |  INCYIncyte Corporation | 68 | 14 | $19.4B |
| 8 | LLYEli Lilly and Company | 62 | 21 | $1.0T |
| 9 | JNJJohnson & Johnson | 50 | 18 | $564.1B |
| 10 |  EXELExelixis, Inc. | 45 | 6 | $12.6B |
Bispecific
424 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | JNJJohnson & Johnson | 54 | 14 | $564.1B |
| 2 | AZNAstraZeneca PLC | 47 | 20 | $275.2B |
| 3 | REGNRegeneron Pharmaceuticals, Inc. | 35 | 8 | $67.0B |
| 4 | AMGNAmgen Inc. | 32 | 8 | $177.2B |
| 5 |  GMABGenmab A/S | 26 | 6 | $15.9B |
| 6 |  GSKGSK plc | 23 | 8 | $102.6B |
| 7 |  DRTSAlpha Tau Medical Ltd. | 21 | — | $884M |
| 8 | PFEPfizer, Inc. | 19 | 5 | $147.6B |
| 9 | MRKMerck & Company, Inc. | 18 | 2 | $302.3B |
| 10 | INCYIncyte Corporation | 17 | 3 | $19.4B |
Vaccine
264 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | SNYSanofi | 41 | 11 | $107.4B |
| 2 | PFEPfizer, Inc. | 36 | 8 | $147.6B |
| 3 | GSKGSK plc | 34 | 11 | $102.6B |
| 4 | S SVASinovac Biotech, Ltd | 23 | 11 | $465M |
| 5 |  MRNAModerna, Inc. | 22 | 4 | $18.6B |
| 6 |  BNTXBioNTech SE | 16 | 4 | $23.3B |
| 7 | MRKMerck & Company, Inc. | 14 | 7 | $302.3B |
| 8 |  VALNValneva SE | 7 | 2 | $544M |
| 9 |  TAKTakeda Pharmaceutical Company Limited | 6 | 3 | $50.9B |
| 10 |  DSGNDesign Therapeutics, Inc. | 4 | — | $685M |
CAR-T
245 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 |  DTILPrecision BioSciences, Inc. | 35 | — | $187M |
| 2 | NVSNovartis AG | 24 | 4 | $277.7B |
| 3 | BMYBristol-Myers Squibb Company | 24 | 5 | $121.4B |
| 4 |  GILDGilead Sciences, Inc. | 16 | 4 | $166.8B |
| 5 | AZNAstraZeneca PLC | 13 | 1 | $275.2B |
| 6 | JNJJohnson & Johnson | 12 | 2 | $564.1B |
| 7 |  KYTXKyverna Therapeutics, Inc. | 12 | — | $527M |
| 8 |  IOVAIovance Biotherapeutics, Inc. | 10 | 1 | $1.8B |
| 9 |  CABACabaletta Bio, Inc. | 6 | — | $595M |
| 10 |  AUTLAutolus Therapeutics plc | 6 | — | $466M |
Recombinant protein
193 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | IOVAIovance Biotherapeutics, Inc. | 11 | 1 | $1.8B |
| 2 |  IBRXImmunityBio, Inc. | 11 | 1 | $7.6B |
| 3 | PFEPfizer, Inc. | 10 | 6 | $147.6B |
| 4 | MRKMerck & Company, Inc. | 10 | 6 | $302.3B |
| 5 | SNYSanofi | 10 | 3 | $107.4B |
| 6 |  BMRNBioMarin Pharmaceutical Inc. | 10 | 3 | $10.5B |
| 7 | JNJJohnson & Johnson | 9 | 5 | $564.1B |
| 8 | AZNAstraZeneca PLC | 9 | 1 | $275.2B |
| 9 |  NVONovo Nordisk A/S | 8 | 1 | $198.9B |
| 10 | ABBVAbbVie Inc. | 6 | 3 | $380.6B |
Gene therapy
184 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 13 | 5 | $277.7B |
| 2 | MRKMerck & Company, Inc. | 10 | 5 | $302.3B |
| 3 |  SRPTSarepta Therapeutics, Inc. | 8 | 3 | $1.8B |
| 4 |  RAREUltragenyx Pharmaceutical Inc. | 7 | 3 | $2.3B |
| 5 | ABBVAbbVie Inc. | 7 | 2 | $380.6B |
| 6 |  CRSPCRISPR Therapeutics AG | 6 | — | $4.9B |
| 7 |  FDMT4D Molecular Therapeutics, Inc. | 6 | — | $450M |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 5 | 1 | $10.5B |
| 9 | PFEPfizer, Inc. | 5 | 4 | $147.6B |
| 10 |  ADVMAdverum Biotechnologies, Inc. | 5 | 2 | $96M |
ADC
170 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | AZNAstraZeneca PLC | 47 | 17 | $275.2B |
| 2 | GILDGilead Sciences, Inc. | 18 | 7 | $166.8B |
| 3 | PFEPfizer, Inc. | 13 | 4 | $147.6B |
| 4 | BNTXBioNTech SE | 10 | 3 | $23.3B |
| 5 | ABBVAbbVie Inc. | 9 | 1 | $380.6B |
| 6 | MRKMerck & Company, Inc. | 9 | 4 | $302.3B |
| 7 |  ONCBeOne Medicines Ltd. | 7 | — | $35.1B |
| 8 | LLYEli Lilly and Company | 6 | 1 | $1.0T |
| 9 | GSKGSK plc | 5 | 3 | $102.6B |
| 10 |  BCYCBicycle Therapeutics plc | 4 | — | $300M |
Peptide
137 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | LLYEli Lilly and Company | 60 | 38 | $1.0T |
| 2 | NVONovo Nordisk A/S | 58 | 21 | $198.9B |
| 3 | SNYSanofi | 2 | — | $107.4B |
| 4 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $67.0B |
| 5 |  UBXUnity Biotechnology, Inc. | 2 | — | $3M |
| 6 |  ALNYAlnylam Pharmaceuticals, Inc. | 1 | — | $38.2B |
| 7 |  VANIVivani Medical, Inc. | 1 | — | $103M |
| 8 |  VNDAVanda Pharmaceuticals Inc. | 1 | 1 | $372M |
| 9 |  IOBTIO Biotech, Inc. | 1 | — | $3M |
| 10 | AZNAstraZeneca PLC | 1 | — | $275.2B |
Oligonucleotide
120 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 29 | 15 | $277.7B |
| 2 | ALNYAlnylam Pharmaceuticals, Inc. | 16 | 4 | $38.2B |
| 3 |  BIIBBiogen Inc. | 14 | 6 | $28.6B |
| 4 |  IONSIonis Pharmaceuticals, Inc. | 11 | 9 | $12.5B |
| 5 | GSKGSK plc | 7 | 2 | $102.6B |
| 6 | AZNAstraZeneca PLC | 6 | 1 | $275.2B |
| 7 | REGNRegeneron Pharmaceuticals, Inc. | 5 | — | $67.0B |
| 8 |  WVEWave Life Sciences Ltd. | 4 | — | $1.2B |
| 9 | RAREUltragenyx Pharmaceutical Inc. | 3 | 2 | $2.3B |
| 10 |  PRAXPraxis Precision Medicines, Inc. | 2 | 1 | $9.6B |
mRNA
91 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | MRNAModerna, Inc. | 38 | 4 | $18.6B |
| 2 | SNYSanofi | 8 | — | $107.4B |
| 3 | PFEPfizer, Inc. | 6 | — | $147.6B |
| 4 | BNTXBioNTech SE | 5 | 1 | $23.3B |
| 5 | MRKMerck & Company, Inc. | 5 | 2 | $302.3B |
| 6 | GSKGSK plc | 4 | — | $102.6B |
| 7 |  BEAMBeam Therapeutics Inc. | 2 | — | $3.0B |
| 8 | S SVASinovac Biotech, Ltd | 2 | — | $465M |
| 9 |  RNACCartesian Therapeutics, Inc. | 2 | 1 | $198M |
| 10 |  ARCTArcturus Therapeutics Holdings Inc. | 2 | — | $217M |
Radioconjugate
74 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | NVSNovartis AG | 38 | 5 | $277.7B |
| 2 |  TLXTelix Pharmaceuticals Limited | 6 | 4 | $3.2B |
| 3 | LLYEli Lilly and Company | 5 | 1 | $1.0T |
| 4 | BMYBristol-Myers Squibb Company | 4 | 1 | $121.4B |
| 5 | AZNAstraZeneca PLC | 3 | — | $275.2B |
| 6 |  LNTHLantheus Holdings, Inc. | 3 | 1 | $6.7B |
| 7 | EXELExelixis, Inc. | 3 | — | $12.6B |
| 8 |  GEHCGE HealthCare Technologies Inc. | 3 | — | $29.2B |
| 9 |  ACIUAC Immune SA | 2 | — | $246M |
| 10 |  AKTSAktis Oncology, Inc. | 2 | — | $1.1B |
Cell therapy
65 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | IOVAIovance Biotherapeutics, Inc. | 10 | 1 | $1.8B |
| 2 | SNYSanofi | 4 | — | $107.4B |
| 3 | INCYIncyte Corporation | 4 | — | $19.4B |
| 4 | TAKTakeda Pharmaceutical Company Limited | 4 | 2 | $50.9B |
| 5 | JNJJohnson & Johnson | 4 | 4 | $564.1B |
| 6 | IBRXImmunityBio, Inc. | 2 | — | $7.6B |
| 7 | NVSNovartis AG | 2 | 1 | $277.7B |
| 8 |  JAZZJazz Pharmaceuticals plc | 2 | — | $15.0B |
| 9 | PFEPfizer, Inc. | 2 | 1 | $147.6B |
| 10 | ONCBeOne Medicines Ltd. | 2 | — | $35.1B |
PROTAC
28 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | PFEPfizer, Inc. | 7 | 2 | $147.6B |
| 2 | ONCBeOne Medicines Ltd. | 4 | 2 | $35.1B |
| 3 |  KYMRKymera Therapeutics, Inc. | 3 | — | $6.5B |
| 4 |  ARVNArvinas, Inc. | 3 | — | $516M |
| 5 |  NRIXNurix Therapeutics, Inc. | 3 | — | $1.8B |
| 6 |  CCCCC4 Therapeutics, Inc. | 2 | — | $394M |
| 7 | NVSNovartis AG | 1 | — | $277.7B |
| 8 | BMYBristol-Myers Squibb Company | 1 | 1 | $121.4B |
| 9 |  SLRXSalarius Pharmaceuticals, Inc. | 1 | — | $5M |
| 10 |  UTHRUnited Therapeutics Corporation | 1 | — | $24.1B |
Cancer vaccine
25 trials| # | Company | Trials | P3 | Mkt Cap |
|---|---|---|---|---|
| 1 | BNTXBioNTech SE | 3 | — | $23.3B |
| 2 | BMYBristol-Myers Squibb Company | 2 | — | $121.4B |
| 3 | REGNRegeneron Pharmaceuticals, Inc. | 2 | — | $67.0B |
| 4 |  CADLCandel Therapeutics, Inc. | 2 | 1 | $585M |
| 5 |  GOVXGeoVax Labs, Inc. | 1 | — | $13M |
| 6 |  CLDXCelldex Therapeutics, Inc. | 1 | — | $2.4B |
| 7 | AMGNAmgen Inc. | 1 | — | $177.2B |
| 8 |  VIRVir Biotechnology, Inc. | 1 | — | $1.5B |
| 9 | INCYIncyte Corporation | 1 | — | $19.4B |
| 10 |  CHRSCoherus Oncology, Inc. | 1 | — | $248M |
About this data: Modality classification is derived from ClinicalTrials.gov sponsor descriptions and intervention metadata. Coverage is currently strongest in Small Molecule, Monoclonal Antibody, and Gene Therapy - finer-grain modalities (ADC, bispecific, CAR-T, oligonucleotide, peptide) are being added in upcoming releases. Companies with fewer than 10 upcoming trials in a modality are not ranked.